New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
07:05 EDTISISIsis Pharmaceuticals initiates Phase 1 study of ISIS-ANGPTL3 Rx
Isis Pharmaceuticals nannounced that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3 Rx, an antisense drug targeting angiopoietin-like 3 protein, an independent risk factor for cardiovascular disease. ISIS-ANGPTL3 Rx is designed to act as a broad dyslipidemia agent. By reducing ANGPTL3, ISIS-ANGPTL3 Rx has the potential to reduce LDL-cholesterol and triglycerides, and to increase insulin sensitivity. Isis plans to evaluate ISIS-ANGPTL3 Rx in patients who have severe metabolic or cardiovascular disease and who would benefit from a drug that simultaneously addresses a variety of adverse lipid and metabolic parameters contributing to their disease.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
07:06 EDTISISIsis Pharmaceuticals initiates phase 1/2 study of ISIS-DMPK Rx
Subscribe for More Information
December 11, 2014
09:28 EDTISISIsis Pharmaceuticals up 3% after CEO appears on Mad Money
Subscribe for More Information
December 8, 2014
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use